Table 1.
Demographic and oncological characteristics of patients with rechallenge ICI after severe irAE.
| n=16 | ||
|---|---|---|
| Age median (range) | 61 (33-88) | |
| Sex (%) | Male | 8 (53) |
| Female | 7 (47) | |
| Primary tumor site (%) | Cutaneous melanoma | 13 (86.8) |
| Mucosal melanoma | 1 (6.6) | |
| Lung | 1 (6.6) | |
| Autoimmune disease (%) | Ulcerative colitis | 1 (6.6) |
| Psoriatic arthritis | 1 (6.6) | |
| None | 13 (86.8) | |
| First ICI (%) | Pembrolizumab | 4 (26.7) |
| Nivolumab | 4 (26.7) | |
| Atezolizumab | 1 (6.6) | |
| Ipilimumab+Nivolumab | 6 (40) | |
| Time to irAE in days, median (range) | 49 (17-246) | |
| Grade of initial irAE (%) | Grade 3 | 15 (100) |
| Grade 4 | 0 (0) | |
| Systemic corticosteroids use (%) | Yes Duration in months, median (range) |
13 (87) 5,5 (2-8) |
| No | 2 (13) | |
| Other treatment for irAE | Intravenous immunoglobulins | 2 |
| Methotrexate | 2 | |
| Infliximab | 1 | |
| Hydroxycloroquine | 1 | |
| Antibiotics | 2 | |
| Hospitalization (%) | Yes | 14 (93.4) |
| Duration in days, median (range) | 13 (4-20) | |
| No | 1 (6.6) |
ICI, immune checkpoint inhibitors; irAE, immune related adverse events.